Varaico: Literature-Extracted Genetic Variants

Gene:GLA
Variant:p.S235C
Back to variants list

GLA

NM_000169.3:p.S235C

Associated Papers

Reducing agalsidase beta infusion time in Fabry patients: low incidence of antibody formation and infusion-associated reactions in an Italian multicenter study.

Mignani R et al.

Orphanet Journal of Rare Diseases, 2024

Globotrioasylsphingosine Levels and Optical Coherence Tomography Angiography in Fabry Disease Patients.

Wiest MRJ et al.

Journal of Clinical Medicine, 2021

Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidase.

Cimmaruta C et al.

Bmc Bioinformatics, 2018

30497360 (PubMed )
Supplement: 12859_2018_2416_MOESM1_ESM.xlsx › ST1

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.

Benjamin ER et al.

Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017

27657681 (PubMed )
Supplement: gim2016122x1.zip › Supplemental_Appendix_2_12152015.xlsx › Classic

The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations.

Citro V et al.

International Journal of Molecular Sciences, 2016

27916943 (PubMed )
Supplement: ijms-17-02010-s001.zip › ijms-157565-supplementary_file_1_done.xlsx › Tabella_aggiornamento

Comparative study of structural changes caused by different substitutions at the same residue on α-galactosidase A.

Saito S et al.

Plos One, 2013

Pharmacological chaperone therapy for Fabry disease.

Ishii S

Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 2012

Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study.

Andreotti G et al.

Orphanet Journal of Rare Diseases, 2010

21138548 (PubMed )
Supplement: 1750-1172-5-36-S1.XLS › data

Novel tools for extraction and validation of disease-related mutations applied to Fabry disease.

Kuipers R et al.

Human Mutation, 2010

20629180 (PubMed )
Supplement: supplement_1.pdf

The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines.

Benjamin ER et al.

Journal of Inherited Metabolic Disease, 2009

Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease.

Altarescu GM et al.

Clinical Genetics, 2001

Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes.

Ashton-Prolla P et al.

Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research, 2000

Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease.

Topaloglu AK et al.

Molecular Medicine (cambridge, Mass.), 1999

Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."